NEW YORK (GenomeWeb) – Sequenom announced today that its subsidiary Sequenom Laboratories has signed an in-network contract with Anthem Blue Cross and Blue Shield in Connecticut, Maine, and New Hampshire to cover insured patients for the company's noninvasive prenatal tests.

The life sciences company said the agreements provide coverage for patients with both high- and average-risk pregnancies in those states, effective March 28.

Further terms of the deal were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.